Scholarlink

<p>Thrombocytopenia remains a formidable clinical challenge across a broad spectrum of medical conditions, as it substantially elevates hemorrhagic risk and complicates established therapeutic protocols. Although platelet transfusions have traditionally served as the cornerstone of management, their utility is frequently constrained by transient efficacy and inherent logistical burdens. The emergence of thrombopoietic agents, particularly second-generation thrombopoietin receptor agonists (TPO-RAs), has shifted the treatment landscape by offering a more direct and targeted way to stimulate platelet production. This review evaluates the mechanisms and clinical utility of contemporary therapies, spanning from recombinant human thrombopoietin (rhTPO) and established TPO-RAs (eltrombopag, romiplostim, and herombopag) to emerging classes such as spleen tyrosine kinase (SYK) and Bruton tyrosine kinase (BTK) inhibitors. We delineate their specific roles in the management of immune thrombocytopenia (ITP), chemotherapy-induced thrombocytopenia (CIT), chronic liver disease (CLD), and aplastic anemia (AA). Despite these advancements, challenges including inconsistent response rates, long-term safety considerations, and accessibility barriers persist. Looking ahead, the field is pivoting toward personalized management strategies and next-generation agents to further refine patient care and optimize clinical outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advances and Clinical Applications of Thrombopoietic Agents

  • 期刊论文

  • 发表日期：

    2026年7月6日

查看全文
  • Jin-huan Xu,
  • Yu-ting Gong,
  • Yi-cheng Zhang,
  • Jia Wei,
  • Li-jun Jiang

摘要

Thrombocytopenia remains a formidable clinical challenge across a broad spectrum of medical conditions, as it substantially elevates hemorrhagic risk and complicates established therapeutic protocols. Although platelet transfusions have traditionally served as the cornerstone of management, their utility is frequently constrained by transient efficacy and inherent logistical burdens. The emergence of thrombopoietic agents, particularly second-generation thrombopoietin receptor agonists (TPO-RAs), has shifted the treatment landscape by offering a more direct and targeted way to stimulate platelet production. This review evaluates the mechanisms and clinical utility of contemporary therapies, spanning from recombinant human thrombopoietin (rhTPO) and established TPO-RAs (eltrombopag, romiplostim, and herombopag) to emerging classes such as spleen tyrosine kinase (SYK) and Bruton tyrosine kinase (BTK) inhibitors. We delineate their specific roles in the management of immune thrombocytopenia (ITP), chemotherapy-induced thrombocytopenia (CIT), chronic liver disease (CLD), and aplastic anemia (AA). Despite these advancements, challenges including inconsistent response rates, long-term safety considerations, and accessibility barriers persist. Looking ahead, the field is pivoting toward personalized management strategies and next-generation agents to further refine patient care and optimize clinical outcomes.